Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71518 | 0.86 | NPSR1 (0.59) | NPSR1L3MBTL1KDM4EKDM4CCA12 | |
| SCHEMBL9632764 | 0.80 | NPSR1 (0.52) | NPSR1L3MBTL1KDM4EKDM4CGAA | |
| SCHEMBL28150097 | 0.78 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL29409978 | 0.78 | NPSR1 (0.50) | NPSR1L3MBTL1KDM4EKDM4CTDP1 | |
| SCHEMBL361255 | 0.78 | KDM4E (0.58) | NPSR1L3MBTL1KDM4EKDM4CALDH1A1 | |
| SCHEMBL360639 | 0.78 | NPSR1 (0.50) | NPSR1L3MBTL1KDM4EKDM4CTDP1 | |
| SCHEMBL162243 | 0.78 | L3MBTL1 (0.53) | NPSR1L3MBTL1KDM4EKDM4CGAA | |
| SCHEMBL31027302 | 0.78 | KDM4E (0.58) | NPSR1L3MBTL1KDM4EKDM4CALDH1A1 | |
| SCHEMBL23888774 | 0.77 | NPSR1 (0.48) | NPSR1L3MBTL1KDM4EKDM4CALDH1A1 | |
| SCHEMBL261104 | 0.77 | NPSR1 (0.48) | NPSR1L3MBTL1KDM4EGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108067191-A | For the reactor assembly of orthophosphates in Adsorption waste water | 北京益清源环保科技有限公司 | 2018-05-25 | — | — | CN | claimed |
| CN-108031441-A | There is the modified activated carbon absorbent of absorption property to the orthophosphates in water body | 北京益清源环保科技有限公司 | 2018-05-15 | — | — | CN | claimed |
| CN-105732524-A | A preparing method of 6-bromo-3-hydroxy-2-pyrazinamide | 青岛市黄岛区中医医院 | 2016-07-06 | — | — | CN | claimed |
| CN-102775358-B | Preparation method of 6-fluoro-3-hydroxy-2-pyrazinamide | SHANDONG QIDU PHARMACEUTICAL | 2015-05-27 | — | — | CN | claimed |
| CN-102603657-B | Preparation method of 6-bromine-3-hydroxyl-2-pyrazinamide | SHANDONG QIDU PHARMACEUTICAL | 2015-02-04 | — | — | CN | claimed |
| CN-102775358-A | Preparation method of 6-fluoro-3-hydroxy-2-pyrazinamide | SHANDONG QIDU PHARMACEUTICAL | 2012-11-14 | — | — | CN | claimed |
| CN-102603657-A | Preparation method of 6-bromine-3-hydroxyl-2-pyrazinamide | SHANDONG QIDU PHARMACEUTICAL | 2012-07-25 | — | — | CN | claimed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2024211836-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | disclosed |
| CN-1539828-A | Nitrogen-contg. heterocyclic carboxamide derivatives or salt thereof | ��ɽ��ѧ��ҵ��ʽ���� | 2004-10-27 | — | — | CN | disclosed |
| US-6787544-B2 | USEFUL FOR PROPHYLAXIS AND THERAPY OF VIRUS INFECTIONS AND ESPECIALLY INFLUENZA VIRUS INFECTIONS | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| CN-1154493-C | Nitrogen-containing heterocyclic carboxamide derivative or salt thereof and antiviral agent containing the same | ��ɽ��ѧ��ҵ��ʽ���� | 2004-06-23 | — | — | CN | disclosed |
| EP-1417967-A1 | NOVEL VIRUS PROLIFERATION INHIBITION/VIRUCIDAL METHOD AND NOVEL PYRADINE NUCLEOTIDE/PYRADINE NUCLEOSIDE ANALOGUE | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-20020013316-A1 | Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-31 | — | — | US | disclosed |
| CN-1313768-A | Nitrogen-containing heterocyclic carboxamide derivative or salt thereof and antiviral agent containing the same | TOYAMA CHEMICAL CO LTD (JP) | 2001-09-19 | — | — | CN | disclosed |
| EP-1112743-A1 | NITROGENOUS HETEROCYCLIC CARBOXAMIDE DERIVATIVES OR SALTS THEREOF AND ANTIVIRAL AGENTS CONTAINING BOTH | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | MALT1, LITAF, IL2 | NPSR1 2968/4885L3MBTL1 4811/4885KDM4E 3981/4885 |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | NPSR1 3684/4885L3MBTL1 3878/4885KDM4E 2459/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | NPSR1 2254/4885L3MBTL1 1344/4885KDM4E 4515/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | NPSR1 2680/4885L3MBTL1 1625/4885KDM4E 4522/4885 |
| US-20020013316-A1 | Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same | ZC3HAV1, EIF2AK2, NSUN2 | NPSR1 1408/4885L3MBTL1 992/4885KDM4E 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.